Gastroenterology

VOQUENZA® provides quicker healing than Lansoprazole, according to an FDA-approved Phase 3 study

A retrospective analysis of data from the US National Inpatient Sample revealed the prevalence of fibromyalgia and chronic fatigue syndrome was significantly increased in patients with IBS compared to those without IBS.

Marla Dubinsky, MD, discusses findings from the LUCENT program and their role in the recent FDA approval of mirikizumab for ulcerative colitis.

Results from both phase 2 trials were presented in poster abstracts at ACG 2023.

In this interview, Remo Panaccione, MD, discusses results from the long-term extension of the GALAXI phase 2 study for guselkumab in Crohn disease and their implications in clinical practice.

Findings were presented in an abstract at ACG 2023, highlighting the importance of addressing bowel urgency in patients with ulcerative colitis.

New data from ACG 2023 shows etrasimod-treated patients were able to achieve UC remission, with or without concomitant steroid treatment at baseline.

Eli Lilly and Company announced the FDA approval of mirikizumab (Omvoh) for moderately and severely active ulcerative colitis in adults on October 26, 2023.

Results showed higher-exposure dupilumab met the study’s primary endpoint for peak esophageal intraepithelial count ≤6 eos/high-power field.

New QUASAR analysis shows patients with intolerance or failed response to advanced therapies nonetheless achieved benefit with guselkumab.

Results presented in a paper at ACG 2023 showed upadacitinib was more effective than ustekinumab for achieving clinical response and endoscopic remission.

A multi-target stool RNA test effectively screened individuals age 45 and older for colorectal cancer and advanced adenomas.

Induction treatment with guselkumab resulted in a rapid onset of efficacy, beginning at week 1 and increasing over time to week 12, for patients with refractory moderately to severely active ulcerative colitis.

Patients with UC and Crohn's disease showed higher drug levels and good acceptance when switching from intravitreal to subcutaneous infliximab.

Etrasimod demonstrated rapid and significant symptomatic improvement, with differences compared to placebo evident as early as 2 days after initiation of treatment in patients with ulcerative colitis.

Completion of prescription app-based cognitive behavioral therapy using Mahana IBS significantly reduced symptom severity and perceived stress for patients with irritable bowel syndrome.

Results from the 104-week extension study were presented at ACG 2023, demonstrating mirikizumab’s favorable safety and efficacy profiles.

Experts recommended the early use of anti-TNF therapy for patients with ulcerative colitis and Crohn disease, offering further input regarding the introduction, optimization, and maintenance of the treatment for patients with IBD.

Switching from biosimilar CT-P13 to SB2 is safe and effective, according to new research. The patients in the study had no significant changes in their psychometric assessments during the 12 month follow up.

Advanced therapies for inflammatory bowel disease, namely small molecules and biologic therapies, did not increase the risk of a major adverse cardiovascular event or venous thromboembolism.

Consumption of fruit and vegetables was found to be protective while consuming sweet snacks and candy along with supercenters and warehouse clubs as a primary food source were determined to be risk factors for early onset colorectal cancer mortality.

The 15 mg dose of tirzepatide was the most efficacious GLP-1 agonist for obesity management in patients without diabetes in a systemic review of data from MEDLINE and Embase databases.

The approval of infliximab-dyyb as a maintenance therapy following IV infliximab for patients with moderately to severely active ulcerative colitis and Crohn disease was announced on October 22, 2023.

Thomas F. Imperiale, MD, discusses the pivotal findings showing improvements to the prior iteration of Cologuard, as well as bettered sensitivity and specificty relative to fecal immunochemical tests.

Presented at United European Gastroenterology Week 2023, results of the retrospective study showed ferric maltol was safe for us in pregnant patients with IBD and iron deficiency anemia.

New phase 1b data supports further investigation into Adiso Therapeutic's prospective treatment.

Post-hoc analysis clarifies efficacy of upadacitinib for patients with moderately to severely active Crohn's disease with a CDAI of 220 or more.

New data presented at ACG 2023 showed an approximate 60% success rate of recurrent C difficile prevention in adults with comorbid conditions including CKD and cardiac disease.

Final data from STARS Nutrition were presented at United European Gastroenterology Week 2023, demonstrating a significant reduction in parenteral support.

Results from the phase 3 ATLANTIS study showed amitriptyline was superior to placebo across multiple symptom-based outcomes for patients with IBS.